# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> Change in Total Recall Score in the Selective Reminding Test. timeframe=12 months. Placebo=5.7 (±8.7); Metformin=9.4 (±8.5). p=0.05

## Failed citation traces

- **alias_match** on `C072` (ref=0): alias 'Change' NOT resolved (drift)
- **alias_match** on `C072` (ref=0): alias 'Recall' NOT resolved (drift)
- **alias_match** on `C072` (ref=0): alias 'Reminding' NOT resolved (drift)

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The citation trace for claim C072 contains critical failures. Specifically, multiple key terms in the claim ('Change', 'Recall', 'Reminding') failed their alias matches, indicating a drift between the claim and the source evidence. Furthermore, the alias resolution for 'Score' to 'DIFENOCONAZOLE' and 'Test' to 'SCHICK TEST CONTROL' is nonsensical in the context of a cognitive assessment (Selective Reminding Test) and suggests the evidence provided is entirely unrelated to the claim's subject matter.

**Flagged claims:** C072

### `domain_skeptic` — `reject` (score 2)

The submission suffers from severe 'off-topic drift' and a complete failure of semantic alignment. While the p-value and numerical data may be extracted from the source, the alias matching reveals a catastrophic failure in domain mapping: 'Score' is resolved to 'DIFENOCONAZOLE' (a fungicide) and 'Test' is resolved to 'SCHICK TEST CONTROL' (a test for erythrasma). This indicates that the evidence being cited is either fundamentally misinterpreted or the mapping process has hallucinated connections to unrelated pharmacological and diagnostic entities.

Furthermore, a p-value of 0.05 is the absolute threshold for significance; framing this as a 'moderate' direct claim without discussing the high standard deviation (±8.7 and ±8.5) relative to the mean difference is an over-claiming of the effect's robustness. The data shows massive overlap between the placebo and treatment groups, making the conclusion clinically fragile.

**Flagged claims:** C072

### `final_judge` — `reject` (score 1)

I align with both the Evidence Auditor and the Domain Skeptic. The citation trace reveals a catastrophic failure in semantic alignment. The resolution of 'Score' to 'DIFENOCONAZOLE' and 'Test' to 'SCHICK TEST CONTROL' is not merely a minor drift but a complete hallucination of domain mapping, linking a cognitive memory test to a fungicide and a dermatological test. This renders the supporting evidence entirely invalid.

Additionally, I agree with the Domain Skeptic's assessment of the data's fragility. With standard deviations nearly equal to or exceeding the means, and a p-value sitting exactly on the threshold of significance (0.05), the claim of a 'moderate' effect is statistically unsupported. The overlap between the groups is too significant to justify the claim as presented.

**Flagged claims:** C072

## References

[33] Metformin in Amnestic Mild Cognitive Impairment (2012). https://clinicaltrials.gov/study/NCT00620191
